Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx Appoints New Member to Board of Directors

NEW YORK, April 3 – Protein chip developer Zyomyx said Tuesday that Raju Kucherlapati has joined its board of directors.

Kucherlapati was a founder of Cell Genesys and Millennium Pharmaceuticals and currently serves as a director for Abgenix, Millennium, and Valentis.

Kucherlapati completed his postdoctoral work at Yale University and was awarded a PhD in genetics from the University of Illinois, Urbana.

Zyomyx of Hayward, Calif., has an agreement with Cambridge Antibody Technology to jointly develop high-density protein chips and is scheduled to begin beta testing its protein chips sometime in the first half of this year.

The privately-held company has raised $32.6 million in private financing. 

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.